News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: Fosun Pharma And TPG Offer $369 Million For Chindex International, Inc. (CHDX)



2/24/2014 9:11:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

February 22, 2014 --Fosun Pharma and TPG, a US private equity company, teamed up to offer $369 million to take China hospital operator Chindex private; Harbin Gloria Pharma acquired Shanghai Huatuo Medical Science, a maker of TCM products, for $170 million; Tonghua Shuanglong Chemical paid $178 million to acquire Jinbao Pharma in a cash and stock deal; Citic Private Equity is reportedly seeking funds to buy Biosensors, a China cardiovascular device company that is worth $1.2 billion; Lee’s Pharma in-licensed China rights to tafoxiparin, a clinical-stage labor-inducing drug from Dilafor of Sweden; Solentim, a UK medical device maker, will market its CellMetric device in China through two China distribution companies; and Dr. Jonathan Wang discussed OrbiMed’s China investment strategies in an exclusive interview with ChinaBio® Today. More details….

Stock Symbols: (SHA: 600196; HK: 2196) (NSDQ: CHDX) (SHE: 002437) (SHE: 300108) (HK: 950)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES